Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.

NCT00837811 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT00837811
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00837811 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Extension Study of Multiple Subcutaneous Doses of LY2127399 in Patients With Rheumatoid Arthritis.
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
February 28, 2009
Completion date
January 31, 2012
Enrollment
182 (actual)
Sites
62

Conditions

As the registry lists them; a condition with its own page is linked.

rheumatoid arthritis